Mansun Law

List of Publications by Citations

72 papers	4,536 citations	34 h-index	67 g-index
79 ext. papers	5,327 ext. citations	10.2 avg, IF	5.3 L-index

#	Paper	IF	Citations
72	Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. *Nature Medicine*, **2008**, 14, 25-7	50.5	466
71	The formation and function of extracellular enveloped vaccinia virus. *Journal of General Virology*, **2002**, 83, 2915-2931	4.9	368
70	Hepatitis C virus E2 envelope glycoprotein core structure. *Science*, **2013**, 342, 1090-4	33.3	300
69	A genetically humanized mouse model for hepatitis C virus infection. *Nature*, **2011**, 474, 208-11	50.4	298
68	Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 6205-10	11.5	256
67	Completion of the entire hepatitis C virus life cycle in genetically humanized mice. *Nature*, **2013**, 501, 237-41	50.4	184
66	Vaccinia virus utilizes microtubules for movement to the cell surface. *Journal of Cell Biology*, **2001**, 154, 389-402	7.3	181
65	Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. *Journal of Virology*, **2010**, 84, 10999-1009	6.6	166
64	Broadly neutralizing antibodies abrogate established hepatitis C virus infection. *Science Translational Medicine*, **2014**, 6, 254ra129	17.5	161
63	Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 9499-504	11.5	113
62	Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. *Journal of General Virology*, **2005**, 86, 1279-1290	4.9	110
61	Ligand-induced and nonfusogenic dissolution of a viral membrane. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 5989-94	11.5	95
60	Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. *Nature Medicine*, **2006**, 12, 1310-5	50.5	92
59	The exit of vaccinia virus from infected cells. *Virus Research*, **2004**, 106, 189-97	6.4	90
58	Comparing antigenicity and immunogenicity of engineered gp120. *Journal of Virology*, **2005**, 79, 12148-63	6.6	86
57	Vaccinia virus cores are transported on microtubules. *Journal of General Virology*, **2003**, 84, 2443-2458	4.9	85
56	Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. *Journal of Virology*, **2007**, 81, 4272-85	6.6	84

55	Vaccinia virus motility. *Annual Review of Microbiology*, **2003**, 57, 323-42	17.5	83
54	Antibody neutralization of the extracellular enveloped form of vaccinia virus. *Virology*, **2001**, 280, 132-42	3.6	74
53	Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33. *Journal of Virology*, **2012**, 86, 13085-8	6.6	67
52	Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread. *Journal of General Virology*, **2002**, 83, 209-222	4.9	62
51	Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. *Hepatology*, **2014**, 60, 1551-62	11.2	60
50	An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. *Journal of General Virology*, **2005**, 86, 991-1000	4.9	55
49	V1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design. *Current Opinion in Virology*, **2019**, 34, 149-159	7.5	51
48	Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity. *Hepatology*, **2016**, 64, 1881-1892	11.2	48
47	Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 12768-12773	11.5	48
46	Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis. *PLoS Pathogens*, **2017**, 13, e1006735	7.6	46
45	Genetic and structural insights into broad neutralization of hepatitis C virus by human V1-69 antibodies. *Science Advances*, **2019**, 5, eaav1882	14.3	46
44	Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy. *Nature Biomedical Engineering*, **2019**, 3, 806-816	19	43
43	Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. *Scientific Reports*, **2015**, 5, 12501	4.9	40
42	Self-assembling peptide nanotubes with antiviral activity against hepatitis C virus. *Chemistry and Biology*, **2011**, 18, 1453-62		40
41	Antibodies against viruses: passive and active immunization. *Current Opinion in Immunology*, **2008**, 20, 486-92	7.8	38
40	Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. *Journal of Virology*, **2014**, 88, 10459-71	6.6	35
39	Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. *Current Opinion in Virology*, **2015**, 11, 148-57	7.5	34
38	Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. *Hepatology*, **2013**, 58, 1587-97	11.2	33

37	Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526. *Journal of Molecular Biology*, **2015**, 427, 2617-28	6.5	32
36	The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein. *Frontiers in Immunology*, **2018**, 9, 1315	8.4	31
35	Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. *Journal of Virology*, **2012**, 86, 11956-66	6.6	30
34	A Lentiviral Vector Allowing Physiologically Regulated Membrane-anchored and Secreted Antibody Expression Depending on B-cell Maturation Status. *Molecular Therapy*, **2015**, 23, 1734-1747	11.7	25
33	Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG. *Journal of Virology*, **2017**, 91,	6.6	25
32	A meta-analysis of the existing knowledge of immunoreactivity against hepatitis C virus (HCV). *PLoS ONE*, **2012**, 7, e38028	3.7	24
31	Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines. *Science Advances*, **2020**, 6, eaaz6225	14.3	23
30	Acidic residues in the membrane-proximal stalk region of vaccinia virus protein B5 are required for glycosaminoglycan-mediated disruption of the extracellular enveloped virus outer membrane. *Journal of General Virology*, **2009**, 90, 1582-1591	4.9	23
29	Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers. *MBio*, **2017**, 8,	7.8	22
28	Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 10039-10047	11.5	22
27	Interrogation of Antigen Display on Individual Vaccine Nanoparticles for Achieving Neutralizing Antibody Responses against Hepatitis C Virus. *Nano Letters*, **2018**, 18, 7832-7838	11.5	22
26	Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A. *PLoS Pathogens*, **2017**, 13, e1006214	7.6	21
25	Studying the binding and entry of the intracellular and extracellular enveloped forms of vaccinia virus. *Methods in Molecular Biology*, **2004**, 269, 187-204	1.4	19
24	Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development. *Gastroenterology*, **2020**, 158, 1058-1071.e6	13.3	18
23	Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells. *Vaccine Journal*, **2012**, 19, 1027-37		17
22	Yaba-like disease virus protein Y144R, a member of the complement control protein family, is present on enveloped virions that are associated with virus-induced actin tails. *Journal of General Virology*, **2004**, 85, 1279-1290	4.9	15
21	Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6. *Virology*, **2014**, 458-459, 190-208	3.6	14
20	Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms. *Journal of Virology*, **2019**, 93,	6.6	14

19	Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp). *Methods in Molecular Biology*, **2019**, 1911, 441-450	1.4	12
18	Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. *Liver Transplantation*, **2016**, 22, 324-32	4.5	12
17	Hepatitis C Virus-Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance. *Journal of Infectious Diseases*, **2019**, 219, 68-79	7	10
16	Optimization of peptide arrays for studying antibodies to hepatitis C virus continuous epitopes. *Journal of Immunological Methods*, **2014**, 402, 35-42	2.5	10
15	Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins. *Immunity*, **2021**, 54, 781-796.e4	32.3	10
14	Low-Cost Peptide Microarrays for Mapping Continuous Antibody Epitopes. *Methods in Molecular Biology*, **2016**, 1352, 67-83	1.4	9
13	An alternate conformation of HCV E2 neutralizing face as an additional vaccine target. *Science Advances*, **2020**, 6, eabb5642	14.3	9
12	Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 7569-7574	11.5	8
11	Detection of Antibodies to HCV E1E2 by Lectin-Capture ELISA. *Methods in Molecular Biology*, **2019**, 1911, 421-432	1.4	4
10	Antibody Responses in Hepatitis C Infection. *Cold Spring Harbor Perspectives in Medicine*, **2021**, 11,	5.4	4
9	A structured RNA motif locks Argonaute2:miR-122 onto the 5Vend of the HCV genome. *Nature Communications*, **2021**, 12, 6836	17.4	2
8	An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development. *Gastroenterology*, **2021**,	13.3	2
7	Evaluation of a Series of Lipidated Tucaresol Adjuvants in a Hepatitis C Virus Vaccine Model. *ACS Medicinal Chemistry Letters*, **2020**, 11, 2428-2432	4.3	2
6	Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening. *Cell Reports*, **2022**, 39, 110859	10.6	2
5	Virus reactivation in a non-cirrhotic HBV patient requiring liver transplantation after cessation of nucleoside analogue therapy.. *Antiviral Therapy*, **2021**, 26, 3-8	1.6	1
4	Identification of Novel Determinants of Neutralization Epitope Shielding for Hepatitis C Virus in Vitro. *Proceedings (mdpi)*, **2020**, 50, 5	0.3	
3	Into the Unknown: A Chemical Biology Approach Provides Mechanistic Insight into HCV Entry. *Cell Chemical Biology*, **2020**, 27, 767-769	8.2	
2	Probing the Antigenicity of HCV Envelope Glycoproteins by Phage Display Antibody Technology. *Methods in Molecular Biology*, **2019**, 1911, 381-393	1.4	

1 Simultaneous Quantification of Hepatitis C Virus Envelope Glycoproteins E1 and E2 by Dual-Color Fluorescence Immunoblot Analysis. *Methods in Molecular Biology*, **2019**, 1911, 295-304 1.4